Marshall Wace’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.57M | Sell |
18,980
-14,237
| -43% | -$4.04M | ﹤0.01% | 1315 |
|
|
2026
Q1 | $9.26M | Buy |
33,217
+21,657
| +187% | +$6.24M | 0.01% | 1016 |
|
|
2025
Q4 | $3.5M | Sell |
11,560
-1,054
| -8% | -$329K | ﹤0.01% | 1318 |
|
|
2025
Q3 | $3.54M | Buy |
12,614
+11,688
| +1,262% | +$3.18M | ﹤0.01% | 1346 |
|
|
2025
Q2 | $223K | Sell |
926
-26,169
| -97% | -$6.19M | ﹤0.01% | 2424 |
|
|
2025
Q1 | $6.6M | Buy |
27,095
+24,816
| +1,089% | +$7.47M | 0.01% | 942 |
|
|
2024
Q4 | $749K | Buy |
+2,279
| New | +$774K | ﹤0.01% | 1872 |
|
|
2024
Q1 | – | Sell |
-6,300
| Closed | -$2.03M | – | 2438 |
|
|
2023
Q4 | $2.03M | Sell |
6,300
-119,350
| -95% | -$37.4M | ﹤0.01% | 1213 |
|
|
2023
Q3 | $45M | Buy |
125,650
+106,037
| +541% | +$40.9M | 0.09% | 229 |
|
|
2023
Q2 | $7.44M | Sell |
19,613
-13,749
| -41% | -$5.6M | 0.01% | 862 |
|
|
2023
Q1 | $16M | Buy |
33,362
+32,767
| +5,507% | +$15.3M | 0.03% | 542 |
|
|
2022
Q4 | $250K | Sell |
595
-172,005
| -100% | -$69.4M | ﹤0.01% | 2626 |
|
|
2022
Q3 | $72M | Sell |
172,600
-52,169
| -23% | -$26M | 0.16% | 131 |
|
|
2022
Q2 | $111M | Sell |
224,769
-242,574
| -52% | -$126M | 0.23% | 87 |
|
|
2022
Q1 | $263M | Buy |
467,343
+133,973
| +40% | +$80.8M | 0.5% | 25 |
|
|
2021
Q4 | $252M | Sell |
333,370
-105,974
| -24% | -$79.3M | 0.47% | 30 |
|
|
2021
Q3 | $328M | Buy |
439,344
+4,245
| +1% | +$3.18M | 1.36% | 2 |
|
|
2021
Q2 | $280M | Sell |
435,099
-133,819
| -24% | -$81.4M | 1.27% | 4 |
|
|
2021
Q1 | $325M | Buy |
568,918
+199,507
| +54% | +$118M | 1.49% | 1 |
|
|
2020
Q4 | $215M | Buy |
369,411
+88,844
| +32% | +$50.6M | 1.17% | 13 |
|
|
2020
Q3 | $145M | Buy |
280,567
+47,465
| +20% | +$24M | 0.93% | 16 |
|
|
2020
Q2 | $105M | Buy |
233,102
+120,850
| +108% | +$53.3M | 0.74% | 22 |
|
|
2020
Q1 | $39.4M | Buy |
112,252
+111,393
| +12,968% | +$41M | 0.39% | 52 |
|
|
2019
Q4 | $318K | Sell |
859
-77,897
| -99% | -$27.5M | ﹤0.01% | 1260 |
|
|
2019
Q3 | $26.2M | Buy |
78,756
+57,281
| +267% | +$18.7M | 0.21% | 112 |
|
|
2019
Q2 | $6.71M | Buy |
+21,475
| New | +$6.43M | 0.06% | 400 |
|
|
2019
Q1 | – | Sell |
-9,196
| Closed | -$2.13M | – | 1715 |
|
|
2018
Q4 | $2.13M | Sell |
9,196
-14,767
| -62% | -$3.96M | 0.02% | 706 |
|
|
2018
Q3 | $7.5M | Buy |
23,963
+20,850
| +670% | +$6.47M | 0.06% | 366 |
|
|
2018
Q2 | $898K | Buy |
+3,113
| New | +$860K | 0.01% | 523 |
|
|
2017
Q3 | – | Sell |
-1,114
| Closed | -$252K | – | 342 |
|
|
2017
Q2 | $252K | Buy |
+1,114
| New | +$243K | 0.01% | 282 |
|
Other funds holding BIO
AI
Marshall Wace's BIO Position: Q2 2026 in Review
Marshall Wace reduced its Bio-Rad Laboratories Class A (BIO) stake by 43% in Q2 2026, selling an estimated $4.04M and leaving 18,980 shares worth $5.57M. The position accounts for ﹤0.01% of the portfolio, ranked #1315.
Marshall Wace first reported a position in BIO in Q2 2017 and has held it in 30 quarters since. The position peaked at $328M in Q3 2021. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.
- Marshall Wace held 18,980 shares of Bio-Rad Laboratories Class A worth $5.57M as of Q2 2026.
- Marshall Wace sold 14,237 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $4.04M.
- Bio-Rad Laboratories Class A made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1315 holding.
- Marshall Wace first reported a position in Bio-Rad Laboratories Class A in Q2 2017 and has held it in 30 quarters since.
- Marshall Wace's Bio-Rad Laboratories Class A position peaked at $328M in Q3 2021.
- 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.